Leustatin (Cladribine)

Cladribine is a purine nucleoside analog that is taken up by lymphocytes and incorporated into DNA, where it inhibits DNA synthesis and repair. This leads to selective depletion of both malignant and pathogenic lymphocytes, thereby reducing disease activity in the targeted conditions.

The dosage regimen for Leustatin is determined individually by the prescribing physician based on the specific indication, disease severity, patient weight, renal and hepatic function, and other clinical factors. No fixed dose can be stated without a medical prescription.

Safety data for cladribine during pregnancy and lactation are limited, and the drug is generally not recommended for use in pregnant or nursing women unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To order Leustatin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to cladribine in hairy cell leukemia is pentostatin, while for multiple sclerosis other disease‑modifying therapies such as interferon‑beta or fingolimod are used. Cladribine offers a short‑course oral or intravenous regimen with a distinct mechanism of selective lymphocyte depletion, which may provide convenience and a different safety profile compared with continuous‑dose agents.

Leustatin must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The solution should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations for injectable medicines.

Leustatin is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The infusion rate and total volume are determined by the prescribing clinician, and the medication is typically given in a controlled clinical setting to monitor for infusion‑related reactions.

The most serious risks of Leustatin include profound lymphopenia leading to severe or opportunistic infections, potential development of secondary malignancies, and rare cases of autoimmune hemolytic anemia. Patients should be closely monitored for signs of infection, blood count changes, and any unexpected hematologic abnormalities throughout treatment.

Leustatin is contraindicated in patients with active severe infections, those receiving live attenuated vaccines, and individuals with known hypersensitivity to cladribine or any component of the formulation. Caution is also advised for patients with severely compromised immune systems, uncontrolled organ dysfunction, or in whom the risk–benefit ratio is unfavorable.